UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                                 WASHINGTON D.C.

                                   FORM 10-QSB

|X|   Quarterly Report Pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934, For the Quarter Ended March 31, 2006

|_|   Transitional Report Pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934

                          Commission File No. 000-28459

                      ADVANCED PLANT PHARMACEUTICALS, INC.

             (Exact name of Registrant as specified in its charter)

               Delaware                            59-2762023
        -------------------                    -------------------
   (State  of other jurisdiction       (I.R.S. Employer Identification Number)
of  incorporation  or  organization)

                 43 West 33rd Street, New York, New York 10001
                     Address of principal executive offices

      Registrant's telephone number, including area code: 212-695-3334

      Indicate by check mark whether the issuer (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities and Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the
issuer was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

                                 Yes |X| No |_|

      As of June 20, 2006, there were issued and outstanding 798,157,996, shares
of Common Stock, $.0007 par value per share.

             Transitional Small Business Disclosure Format Yes |_| No |X|

      Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act) Yes |_|  No |X|

<PAGE>

                      ADVANCED PLANT PHARMACEUTICALS, INC.

                                      INDEX

<TABLE>
<CAPTION>
                                                                                 PAGE
                                                                                NUMBER
                                                                                ------
<S>                                                                              <C>
PART I.  FINANCIAL INFORMATION

Item 1.  Condensed financial statements     (unaudited)

         Condensed Balance sheet as of March 31, 2006                             3

         Condensed Statements of operations for the three months
                  ended March 31, 2006 and 2005                                   4

         Condensed Statements of cash flows for the three months ended
             March 31, 2006 and 2005                                              5

      Notes to the condensed financial statements                                 7

Item 2.  Management's Discussion and Analysis of Financial
         Condition and Results of Operations                                      11

Item 3.   Controls and Procedures                                                 15

PART II.  OTHER INFORMATION                                                       16

SIGNATURES                                                                        17
</TABLE>

<PAGE>

                                     PART I

ITEM 1. CONDENSED FINANCIAL STATEMENTS

Item 1. Financial Statements

              ADVANCED PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES

                           CONSOLIDATED BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                                     March 31,     December 31,
                                                                                      2006             2005
                                                                                  ------------    ------------
                                                                                   Unaudited       (Restated)
                                     ASSETS
CURRENT ASSETS
<S>                                                                               <C>             <C>
   Cash and cash equivalents                                                      $     25,567    $     11,688
    Accounts receivable                                                                                  1,188
   Prepaid expenses - officers                                                          24,850          31,550
   Prepaid offering costs                                                                5,000
                                                                                  ------------    ------------
         Total Current Assets                                                           55,417          44,426

OFFICE EQUIPMENT, net of accumulated depreciation of $3,221
    and $2,942, respectively                                                             1,132           1,411
OTHER ASSETS
    Goodwill                                                                            10,406          10,406
   Due from related company                                                             11,250           9,000
    Other assets                                                                         7,144           7,144
                                                                                  ------------    ------------
                                                                                        28,800          26,550
                                                                                  ------------    ------------
          Total Assets                                                            $     85,349    $     72,387
                                                                                  ============    ============

                    LIABILITIES AND STOCKHOLDERS' DEFICIENCY

CURRENT LIABILITIES
   Bank overdraft                                                                 $      8,096    $      7,977
   Accounts payable                                                                    218,301         192,371
   Accrued expenses                                                                    269,976         229,794
   Accrued expenses - officers                                                       1,331,986       1,220,481
    Due to stockholder - asset acquisition                                           1,315,000       1,315,000
   Deposits                                                                            150,000
   Loans payable - stockholders                                                        369,290         369,290
                                                                                  ------------    ------------
         Total Current Liabilities                                                   3,662,649       3,334,913

DEFERRED CREDIT                                                                      4,610,105       4,286,105

STOCKHOLDERS' DEFICIENCY
    Preferred stock, authorized 10,000,000 shares; $0.0007 par value; 5,000,000
        shares issued and outstanding at March 31,
        2006 and December 31, 2005                                                       3,500           3,500
   Common stock, authorized 880,000,000
        shares; $0.0007 par value; 798,157,996
        shares issued and outstanding at March 31,
        2006 and December 31, 2005                                                     558,711         558,711
   Additional paid-in capital                                                       14,681,548      14,681,548
   Accumulated deficit                                                             (23,431,164)    (22,792,390)
                                                                                  ------------    ------------

    Total Stockholders' Deficiency                                                  (8,187,405)     (7,548,631)
                                                                                  ------------    ------------
          Total Liabilities and Stockholders' Deficiency                          $     85,349    $     72,387
                                                                                  ============    ============
</TABLE>

                 See accompanying notes to financial statements.
<PAGE>

              ADVANCED PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES

                CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

<TABLE>
<CAPTION>
                                                     For the Three Months Ended
                                                             March 31,
                                                      2006             2005
                                                  -------------    -------------
<S>                                               <C>              <C>
REVENUE - SALES                                   $       1,976    $       2,130
COSTS AND EXPENSES
    Cost of goods sold                                    1,122
   Salaries and consulting fees - officers              266,700           79,800
   Selling, general and administrative expenses         369,728          223,452
   Depreciation                                             279              279
                                                  -------------    -------------
           Total Costs and Expenses                     636,707          304,653
                                                  -------------    -------------

NET OPERATING LOSS                                     (634,731)        (302,523)

OTHER EXPENSE
   Interest expense                                      (4,043)
                                                  -------------    -------------

NET LOSS                                          $    (638,774)   $    (302,523)
                                                  =============    =============
NET LOSS PER SHARE OF COMMON
   STOCK (basic and fully diluted)                $      (0.001)   $      (0.001)
                                                  =============    =============

WEIGHTED AVERAGE NUMBER OF COMMON
   SHARES OUTSTANDING (basic and fully diluted)     798,157,996      786,269,107
                                                  =============    =============
</TABLE>

                 See accompanying notes to financial statements.
<PAGE>

              ADVANCED PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES

                CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

<TABLE>
<CAPTION>
                                                                For the Three Months Ended
                                                                       March 31,
                                                                  2006            2005
                                                             ------------    ------------
CASH FLOWS FROM OPERATING ACTIVITIES
<S>                                                          <C>             <C>
   Net loss                                                  $   (638,774)   $   (302,523)
   Adjustments to reconcile net loss to cash flows
      used in operating activities
         Stock issued for services                                324,000         106,803
         Depreciation expense                                         279             279
   Changes in assets and liabilities:
       Decrease in accounts receivable                              1,188             306
       (Decrease) in inventory                                                     (1,391)
     Decrease in prepaid expenses - officers                        6,700
     Increase in prepaid offering costs                            (5,000)
     Increase in due from related company                          (2,250)
     Increase in accounts payable                                  25,930           7,686
     Increase in accrued expenses                                  40,182          11,746
     Increase in accrued expenses - officers                      111,505          55,550
                                                             ------------    ------------
       Net cash used in operating activities                     (136,240)       (121,544)

CASH FLOWS FROM INVESTING ACTIVITIES
   Cash paid for office equipment
   Cash paid for intangible assets
   Due from related parties                                                        (1,000)
                                                             ------------    ------------
       Net cash (used in) provided by investing activities                         (1,000)

CASH FLOWS FROM FINANCING ACTIVITIES
   Bank overdraft                                                     119           2,291
   Loans payable - stockholders' - net                                             99,850
   Proceeds from deposits                                         150,000
   Proceeds from issuance of common stock                                          20,000
                                                             ------------    ------------
       Net cash provided by financing activities                  150,119         122,141
                                                             ------------    ------------
       Net increase (decrease) in cash                             13,879            (403)
CASH AT BEGINNING OF PERIOD                                        11,688           1,045
                                                             ------------    ------------

CASH AT END OF PERIOD                                        $     25,567    $        642
                                                             ============    ============
</TABLE>

                 See accompanying notes to financial statements.
<PAGE>

              ADVANCED PLANT PHARMACEUTICALS, INC AND SUBSIDIARIES

          CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (CONTINUED)

<TABLE>
<CAPTION>
                                                              For the Three Months Ended
                                                                        March 31,

                                                                    2006             2005
                                                                -------------     ------------
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
<S>                                                                                <C>

   NON-CASH INVESTING AND FINANCING ACTIVITIES

     Issuance of common stock for services                                         $106,803

     Issuance of preferred stock in payment of loans payable
          to stockholders                                                            10,000

      Issuance of preferred stock in payment of accrued expenses
        to stockholders                                                              10,000

     Purchase of intangible assets for loan payable to stockholder                   19,000

     Issuance of Mazal common stock for services classified as
       a deferred credit                                             $324,000

</TABLE>
                 See accompanying notes to financial statements.
<PAGE>

             ADVANCED PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES

                          NOTES TO FINANCIAL STATEMENTS
                                 March 31, 2006

1. CONDENSED FINANCIAL STATEMENTS

In the opinion of the Company, the accompanying unaudited condensed financial
statements include all adjustments (consisting only of normal recurring
accruals) which are necessary for a fair presentation of the results for the
periods presented. Certain information and footnote disclosure, normally
included in the financial statements prepared in accordance with generally
accepted accounting principles, have been condensed and omitted. The results of
operations for the three months ended March 31, 2006 are not indicative of the
results of operations for the year ended December 31, 2006. The condensed
financial statements should be read in conjunction with the Company's financial
statements included in its annual Form 10 KSB for the year ended December 31,
2005.

2. STOCK WARRANTS

At March 31, 2006, the Company had outstanding warrants to purchase 7,000,000
shares of the Company's common stock at a price of $.03 per share. The warrants
are exercisable and expire at various dates through 2007.

3. COMMITMENTS AND CONTINGENCIES

The Company has employment agreements with nine employees, and a consulting
contract with a key consultant, who are also stockholders of the Company and
Mazal. At March 31, 2006, the Company has a total liability for accrued salaries
and consulting expense to stockholders of $1,221,200. There could be certain
payroll tax liabilities owed to the IRS on some of the payments for services to
certain consultants that were paid in prior years, pursuant to these employment
agreements.

4. DEPOSITS

The deposits at March 31, 2006 in the amount of $150,000 represent deposits to
acquire 200,000 shares of common stock in Mazal at $0.25 per share pursuant to a
Securities Purchase Agreement, and an additional 400,000 shares of common stock
in Mazal at $0.25 per share for which there is no written agreement. The
deposits are non-interest bearing.

5. ISSUANCE OF COMMON STOCK

On January 24, 2006, Mazal issued 200,000 shares of its common stock to a
consultant at $1.08 per share. The aggregate remuneration of $216,000 has been
treated as stock based compensation and expensed in the current period.

On January 25, 2006, Mazal issued 100,000 shares of its common stock to its
President at $1.08 per share. The aggregate remuneration of $108,000 has been
treated as stock based compensation and expensed in the current period.

<PAGE>

              ADVANCED PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES

                          NOTES TO FINANCIAL STATEMENTS
                                 March 31, 2006

6. GOING CONCERN UNCERTAINTY AND MANAGEMENT'S PLANS

As reflected in the accompanying financial statements, the Company has current
liabilities in excess of current assets of $3,607,232, resulting in negative
working capital and an accumulated deficit of $23,431,164. Management is
presently seeking to raise permanent equity capital in the capital markets to
eliminate negative working capital and provide working capital. Failure to raise
equity capital or secure some other form of long-term debt arrangement will
cause the Company to further increase its negative working capital deficit and
could result in the Company having to curtail or cease operations. Additionally,
even if the Company does raise sufficient capital to support its operating
expenses and generate revenues, there can be no assurances that the revenue will
be sufficient to enable it to develop business to a level where it will generate
profits and cash flows from operations. These matters raise substantial doubt
about the Company's ability to continue as a going concern. However, the
accompanying financial statements have been prepared on a going concern basis,
which contemplates the realization of assets and satisfaction of liabilities in
the normal course of business. These financial statements do not include any
adjustments relating to the recovery of the recorded assets or the
classification of the liabilities that might be necessary should the Company be
unable to continue as a going concern.

7. SUBSEQUENT EVENT

In connection with a private placement on April 25, 2006, Mazal issued 400,000
shares of its common stock at $0.25 per share realizing $100,000.

<PAGE>

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS

Background

Advanced Plant Pharmaceuticals, Inc. (the "Company") was incorporated in the
State of Delaware in 1986, under the name Ventra Management, Inc. On July 20,
1994, we amended our Certificate of Incorporation to change our name to Advanced
Plant Pharmaceuticals, Inc.

Description of Business

The Company continues to focus on the research and development of plant based
dietary supplements. In July 1999, the Company acquired exclusive rights and
interests to a thirteen-step process, which utilizes virtually all of the
nutrients found in plants to manufacture natural herbal dietary supplements. The
purchase price for the thirteen step process was 12,000,000 shares of common
stock of the Company. The shares were issued on February 13, 2001. Further, the
Company is required to issue an additional 6,000,000 shares of common stock when
marketing of the product commences. The Company intends to use this process to
manufacture products that it hopes to distribute worldwide through various sales
distribution contracts.

On February 28, 2000, the Company entered into an Asset Purchase Agreement with
Dr. Bielory to purchase his various allergy and nasal formulations. This
agreement was approved by the Board of Directors on September 6, 2000. Dr.
Bielory was granted a five year option to purchase an aggregate of 18,000,000
shares of the Company's common stock at an exercise price of $180.00. Dr.
Bielroy exercised an option for 12,000,000 shares in the first quarter of 2001.

Sinusol, being the formulation purchased from Dr. Bielory, is a generalized base
solution for the development of an extensive line of specialty products related
to allergy and sinus conditions. The ingredients include a mixture of gently
pH-balanced essential mineral oils that combat the various symptoms related to
allergies and sinus disorders, including congestions, irritated nasal mucosa and
bacterial and fungal infections. Specialized advanced formulations are being
reviewed for patent submission.

In addition to Sinusol, the Company is also currently marketing its Lo-Chol
product. Lo-Chol's formula is derived from the "whole plant" parts of six
selected plants that work in concert to help tip your lipid balance (good and
bad cholesterol) towards a more normal level. These six plants are
synergistically combined using a proprietary "whole plant technology" (a special
pharmaceutical-grade process) that delivers virtually all the natural
phyto-chemicals and active ingredients in the plants. Unlike almost all other
herbal supplements on the market, Lo-Chol does not contain any extracts.
Instead, it utilizes the entire part of a specific plant that is processed and
standardized to deliver optimum potency and nutritional benefits.

Recent Developments

In January 2004, the Company acquired a 44% interest in Amazing Nutritionals,
Inc., a development stage company, whereby APPI sold Amazing all of the rights,
title, patents, trademarks, processes and related items of LHM123 which is a
natural composition for the treatment of senile dementias in consideration for
3,300,000 shares of Amazing's common stock.

In December 2004, the Company acquired a 99% interest in Mazal Plant
Pharmaceuticals, Inc. ("Mazal"), a development stage company, whereby APPI sold
Mazal all of its rights relating to or connected with developing, manufacturing
and distributing of three of its products, plant based compositions designed to
treat elevated cholesterol, leukemia and Alzheimer's disease in consideration
for 7,000,000 shares of Mazal's common stock and a receivable of $50,000.

On June 6, 2005, the Company consummated the transactions contemplated by the
Share Exchange Agreement dated as of May 2005 (the "Share Exchange Agreement")
by and among the Company, Akid Corporation ("Akid") and James B. Wiegand.
Pursuant to the Share Exchange Agreement, the Company sold its entire ownership
interest in 7,000,000 shares of the common stock of Mazal to Akid. In exchange,
Akid agreed to issue to the Company 20,000,000 shares (the "Exchange Shares") of
Akid's common stock. Following the consummation of such share exchange, the
Company holds a majority of the issued and outstanding common shares of Akid,
and Akid holds a majority of the issued and outstanding common shares of Mazal.
<PAGE>

Akid issued to the Company 17,500,000 of the Exchange Shares at the closing, and
agreed to issue the remaining 2,500,000 of the Exchange Shares upon increasing
its authorized common stock from 20,000,000 shares to 40,000,000 shares.

Results of Operations

Results of Operations - Three Months Ended March 31, 2006 Compared to the Three
Months Ended March 31, 2005.

Revenues

Revenues generated during the three months ended March 31, 2006, aggregated
$1,976, as compared to $2,130 for the three months ended Mach 31, 2005. The
decrease of $154 in revenues from the comparable period in the prior year is
primarily due to a decrease in marketing due to a lack of funding.

Costs of Goods Sold

Cost of Goods Sold for the three months ended March 31, 2006 aggregated $-0- as
compared to $1,122 for the three months ended March 31, 2005. The decrease for
the three months ended March 31, 2006 is the result of a decrease in sales of
our products.

Operating Expenses

Operating Expenses incurred for the three months ended March 31, 2006,
aggregated $637,707 as compared to $304,653 for three months ended March 31,
2005, which is an increase of $333,054. This increase was primarily due to an
increase in the issuance of stock for services and the payment of fees for
officers and consultants.

Net Loss and Loss Per Common Share

The net loss and the loss per common share was $638,731 and $.001 for the three
months ended March 31, 2006, as compared to net loss of $302,523 and $.001 for
the three months ended March 31, 2005. This increase was due primarily to the
increase in the issuance of stock for services and the payment of fees to
officers and consultants.

Liquidity and Capital Resources

At March 31, 2006, we had working capital deficit of $3,577,300 as compared with
$3,282,188 at December 31, 2005. The increase in the working capital deficit is
primarily the result of an increase in accrued expenses.

We have historically sustained our operations and funded our capital
requirements with the funds received from the sale of our products, loans
received from related parties and the sale of our securities. We will still need
additional investments in order to continue operations. Additional investments
are being sought, but we cannot guarantee that we will be able to obtain such
investments.

Financing transactions may include the issuance of equity or debt securities,
obtaining credit facilities, or other financing mechanisms. However, the trading
price of our common stock and the downturn in the U.S. stock and debt markets
could make it more difficult to obtain financing through the issuance of equity
or debt securities. Even if we are able to raise the funds required, it is
possible that we could incur unexpected costs and expenses, fail to collect
significant amounts owed to us, or experience unexpected cash requirements that
would force us to seek alternative financing. Further, if we issue additional
equity or debt securities, stockholders may experience additional dilution or
the new equity securities may have rights, preferences or privileges senior to
those of existing holders of our common stock. If additional financing is not
available or is not available on acceptable terms, we will have to curtail our
operations again.

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles
generally accepted in the United States requires management of the Company to
make assumptions, estimates and judgments that affect the amounts reported in
the financial statements, including the notes thereto, and related disclosures
of commitments and contingencies, if any. The Company considers its critical
accounting policies to be those that require the more significant judgments and
estimates in the preparation of the Company's financial statements, including
the following: valuation of inventories and intangible assets, valuation of
stock options and warrants, and valuation of all accrued liabilities including
payroll taxes and other contingent liabilities. Management relies on historical
experience and on other assumptions believed to be reasonable under the
circumstances in making its judgment and estimates. Actual results could differ
materially from those estimates.
<PAGE>

ITEM 3 - CONTROLS AND PROCEDURES

As of the end of the period covered by this report, we conducted an evaluation,
under the supervision and with the participation of our chief executive officer
and principal financial officer of our disclosure controls and procedures (as
defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act). Based upon
this evaluation, our chief executive officer and principal financial officer
concluded that our disclosure controls and procedures are effective to ensure
that information required to be disclosed by us in the reports that we file or
submit under the Exchange Act is recorded, processed, summarized and reported,
within the time periods specified in the Commission's rules and forms. There was
no change in our internal controls or in other factors that could affect these
controls during our last fiscal year that has materially affected, or is
reasonably likely to materially affect, our internal control over financial
reporting.

<PAGE>

                                     PART II

ITEM 1 - LEGAL PROCEEDINGS

From time to time, the Company is a party to litigation or other legal
proceedings that it considers to be a part of the ordinary course of its
business. The Company is not involved currently in legal proceedings that could
reasonably be expected to have a material adverse effect on its business,
prospects, financial condition or results of operations except as set forth
below. We may become involved in material legal proceedings in the future.

ITEM 2 - CHANGES IN SECURITIES

None

ITEM 3 - DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None

ITEM 5 - OTHER INFORMATION

None

ITEM 6. - EXHIBITS

      (a)   Exhibits

      31.1  Certification of the Chief Executive Officer and Principal Financial
            Officer of Advanced Plant Pharmaceuticals, Inc. pursuant to Section
            302 of the Sarbanes-Oxley Act of 2002.

      32.1  Certification of the Chief Executive Officer and Principal Financial
            Officer of Advanced Plant Pharmaceuticals, Inc. pursuant to Section
            906 of the Sarbanes-Oxley Act of 2002.

<PAGE>

                                   SIGNATURES

      In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                          ADVANCED PLANT PHARMACEUTICALS, INC.

                          By:  /s/ David Lieberman
                               --------------------------------------------
                               David Lieberman, Chief Executive Officer and
                               Principal Financial Officer

Dated: June 21, 2006